CLARITY 2.0 Supplementary Appendix

Table of Contents

CLARITY 2.0 Trial Investigators

Steering Committee: Arlen Wilcox, Abhinav Bassi, Carol Pollock, Cheryl Jones, Greg J Fox, Louise M Burrell, Meg J Jardine, Sanjay D'Cruz, Sharifah Faridah Syed Omar, Thomas L Snelling, Vinay Rathore, Vivekanand Jha.

Central Coordinating Committee:
Meg J Jardine, Vivekanand Jha, Abhinav Bassi, Arlen Wilcox, Thomas L Snelling, Mark Jones, James Totterdell, Nikita Bathla, Katrina Diamante, Gerard Estivill Mercade, Rui Xie, Aishwarya Nair, Annelise Decaria, Nicola Abignano, Vinay Rathore, Atul Jindal, Sabah Siddiqui, Suprava Patel, Anjulata Sahu, Ashpak Bangi, Yasmeen Shaikh, Manish Kumar Jain, Madhavender Jain, Kapil Soni, Shivam R Kanje, Sanjeev Kumar Vimal, K. Kalyan Chakravarthy, P. Sathish Babu, Sanjay D'Cruz, Yuvraj Singh Cheema, Merlin Moni, Sivapriya G Nair, Sradha Kotwal.

Drug Safety Monitoring Board: Richard Haynes, Gagandeep Kang, Guy Thwaites, Natalie Staplin, Stephane Heritier

Figure S1: Candesartan titration algorithm



SBP, systolic blood pressure; K, seum potassium level; eGFR, estimated glomerular filtration rate; RAASI, renin angiotensin aldosterone system inhibitor; CCB, calcium channel blocker

Figure S2: Participant flow in the CLARITY 2.0 trial until assessment of primary outcome



SBP = systolic blood pressure, eGFR = estimated glomerular filtration rate
* The single screen failure received no investigational medicine product and was not followed up.

Table S2: Modified World Health Organisation Clinical Progression Scale (WHO Scale) scores at Day 60, 90 and 180 in people with COVID-19 randomised to DMX-200, or placebo, on a background of candesartan therapy

WHO Scale Score	Statistic	At Day 60			At Day 90			At Day 180		
		DMX-200 n=25	Placebo n=25	Total n=49	DMX-200 n=25	Placebo n=25	Total n=49	DMX-200 n=25	Placebo n=25	Total n=49
1. Not hospitalised, no limitations on activities	n (%)	21 (84)	22 (92)	43 (88)	24 (96)	22 (92)	46 (94)	23 (92)	23 (96)	46 (94)
2. Not hospitalised, limitation on activities	n (%)	3 (12)	2 (8)	5 (10)	0 (0)	2 (8)	2 (4)	1 (4)	1 (4)	2 (4)
3. Hospitalised, not requiring supplemental oxygen	n (%)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
4. Hospitalised, requiring supplemental oxygen by mask or nasal prongs	n (%)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
5. Hospitalised, on non-invasive ventilation or high-flow oxygen devices	n (%)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
6. Hospitalised, requiring intubation and mechanical ventilation	n (%)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
7. Hospitalised, on invasive mechanical ventilation and extracorporeal membrane oxygenation	n (%)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
8. Death	n (%)	1 (4)	0 (0)	1 (2)	1 (4)	0 (0)	1 (2)	1 (4)	0 (0)	1 (2)

ARB = angiotensin receptor blocker

Table S3: Adverse events among study participants

Adverse Event	DMX-200 and Candesartan	Placebo and Candesartan	Total
Vertigo	2		2
Adult respiratory distress syndrome	1		1
Hypertension	1		1
Gastritis	1		1
Palpitations	1	1	2
Pneumonitis		1	1
Creatinine increased		1	1
Vomiting		1	1
Fever		1	1

None of the adverse events were classified as serious.